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This study provides the first robust data that the antibody response of dogs vaccinated with Nobivac
Rabies vaccine stored for several months at high temperatures (up to 30 C) is not inferior to that of dogs
vaccinated with vaccine stored under recommended cold-chain conditions (2–8 C). A controlled and ran-
domized non-inferiority study was carried out comparing the four-week post vaccination serological
responses of Tanzanian village dogs inoculated with vaccine which had been stored at elevated temper-
atures for different periods of time with those of dogs vaccinated with the same product stored according
to label recommendations. Specifically, the neutralizing antibody response following the use of vaccine
which had been stored for up to six months at 25 C or for three months at 30 C was not inferior to that
following the use of cold-chain stored vaccine. These findings provide reassurance that the vaccine is
likely to remain efficacious even if exposed to elevated temperatures for limited periods of time and,
under these circumstances, it can safely be used and not necessarily destroyed or discarded. The avail-
ability of thermotolerant vaccines has been an important factor in the success of several disease control
and elimination programs and could greatly increase the capacity of rabies vaccination campaigns to
access hard to reach communities in Africa and Asia. We have not confirmed a 3-year duration of immu-
nity for the high temperature stored vaccine, however because annual re-vaccination is usually practiced
for dogs presented for vaccination during campaigns in Africa and Asia this should not be a cause for con-
cern. These findings will provide confidence that, for rabies control and elimination programs using this
vaccine in low-income settings, more flexible delivery models could be explored, including those that
involve limited periods of transportation and storage at temperatures higher than that currently
recommended.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Canine-mediated human rabies is a neglected tropical zoonotic
disease [1] responsible for an estimated 59,000 deaths and 8.6 bil-
lion USD in economic losses annually [2]. The area with the highest
incidence (3.6/100,000) is thought to be rural Africa [2,3]. This toll
is made more tragic by the fact that highly effective vaccines, when
used to protect domestic dogs in endemic countries, are able to
eliminate the disease at source and, when used as post-exposureprophylaxis (PEP), can protect humans following bites from rabid
animals [4].
Where annual canine vaccination is implemented, modeling
and empirical data suggests that a coverage of 70% of the domestic
dog population during annual vaccination campaigns will be suffi-
cient to control and eliminate canine rabies [5,6]. While reaching
this target has been shown to be feasible in most demographic set-
tings in Africa and Asia [7], challenges still remain. Even small gaps
in vaccination coverage can significantly delay time to elimination
[8]. Therefore, where vaccination strategies rely on delivery
through annual campaigns, a low turnout in only a few communi-
ties (that can arise, for example, through ineffective advertising
or poor timing [9]) can jeopardise the success of the wider
programme.
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tion campaigns are expensive to implement, with high fixed costs,
often associated with personnel and vehicle use, resulting in costs
ranging from $1.18 to $6.36 for each dog vaccinated [9,10]. Fur-
thermore, due to the requirement of storing vaccines according
to label recommended ‘cold-chain’ conditions (2–8 C), the reach
of the campaigns is limited to areas within easy reach of facilities
that can store veterinary vaccines under stable and reliable refrig-
eration. Consequently developments that increase the flexibility
with which vaccines can be delivered to and stored in communities
may result in improved coverage and are likely to reduce the rate
at which the inter-campaign coverage declines.
The cold-chain was originally devised as a set of guidelines that
could be implemented worldwide to ensure that vaccines dis-
tributed through the World Health Organisation’s Expanded Pro-
gramme on Immunization [11] were handled and stored in
consistent conditions [12]. The approach was relatively simple:
keep all vaccines within the temperature range 2–8 C. However,
what started as a means of protecting the potency of vaccines dur-
ing distribution slowly led to the emergence of a dogmatic view of
how vaccines should be stored. As a result the planning of cam-
paigns rarely considers the thermotolerance of specific vaccines,
which limits strategic options and the flexibility with which vacci-
nes are handled in the field [12]. Moreover, immunization pro-
grams typically require significant investment in infrastructure
and management, including widely distributed refrigeration units
for storage and cooler units for transportation. In many parts of
the world, where electricity provision is poor, refrigeration units
powered by kerosene, gas or solar power may be expensive, unre-
liable, or not available, constraining the use of vaccines in remote
communities and limiting how vaccination strategies can be
designed [13].
The development of thermotolerant vaccines that can be stored
at ambient temperatures for extended periods of time could allevi-
ate some of these constraints. In addition, with studies estimating
up to 18% of total vaccination costs can be eliminated by the use of
thermostable vaccines [14], their deployment may result in consid-
erable economic savings. Successful examples of thermotolerant
formulations being used to deliver vaccines in hard-to-reach com-
munities in Africa and Asia include meningitis A [13] and hepatitis
B vaccines for children [15–19], and Newcastle disease vaccines for
chickens [20]. Moreover, the development of thermotolerant for-
mulations, that enabled novel storage solutions to be developed
and that, critically, empowered local communities to deliver their
own campaigns, played a pivotal role in the eradication of small
pox and rinderpest [21,22]. A thermotolerant rabies vaccine could
have the same transformative effect for the planned elimination of
canine-mediated human rabies.
The aim of this study, therefore, was to investigate the thermo-
tolerance of the Nobivac Rabies vaccine, commonly used in mass
dog rabies vaccination campaigns around the world. Our principle
objective was to determine whether the immunological response
elicited by doses stored under non-cold-chain conditions was not
inferior to the response elicited by doses of the same vaccine
stored under normal cold-chain conditions.2. Methods
To achieve this objective a controlled and randomized non-
inferiority trial was carried out. The study compared the serologi-
cal response at four weeks post vaccination in Tanzanian village
dogs inoculated with a vaccine (Nobivac Rabies, MSD Animal
Health, Boxmeer, The Netherlands) which had been stored at ele-
vated temperatures for different periods of time, with the responsein similar dogs vaccinated with the same product stored according
to label recommendations (at 2–8 C).
2.1. Sample size calculations
The trial comprised seven groups of dogs each receiving Nobi-
vac Rabies vaccine stored under group specific conditions
(described below). From a previous study, which involved western
European pet dogs [23], relatively comparable to the Tanzanian pet
dogs used in this study, forty 21-day post-vaccination titres were
compiled. The geometric mean of the titres, which appeared log-
normally distributed, was 3.7 IU/ml (1.89 log2; SD of 2.02 log2).
Based on this, sample size calculations estimated that 40 dogs
per group would give a power of more than 80% to establish
non-inferiority to a margin of 1.2 log2. This test (based on the
lower limit of the one-sided 95% confidence interval) is equivalent
to requiring for each comparison that the difference between log
titres of the elevated storage group and the cold-chain reference
will be >1.2 log2. Titre values occurring at this limit will be
approximately 1.89 (the ‘normal’ level of historical data) minus
1.2 log2. This value equals 0.69 log2 (or 1.6 IU/ml), still well above
the defined minimum protective level of 0.5 IU/ml [24]. With an
assumed loss-to-follow-up of approximately 20%, the number of
dogs recruited into the first phase of the study (day-zero) was
increased to 50 per group (total dogs = 350). In summary the trial
was powered to detect a difference of more than 1.2 log2 titre units
between dogs receiving Nobivac Rabies vaccine stored under
cold-chain conditions and those receiving vaccine stored outside
of the cold-chain.
2.2. Preparation of stored vaccines
The vaccine storage conditions for each of the seven groups
were as follows:
1. Vaccine stored at 2–8 C (normal cold-chain conditions)
2. Vaccine stored at 25 C for three months (90 days)
3. Vaccine stored at 25 C for six months (180 days)
4. Vaccine stored at 30 C for three months
5. Vaccine stored at 30 C for six months
6. Vaccine stored at 37 C for three months
7. Vaccine stored at 37 C for six months
Warehouse storage at 2–8 C was used before and after all incu-
bation steps and as the storage for group 1 vaccines. For the 90 and
180 day incubation at elevated temperatures a Hielkema room was
used for storage at 25 C (±3 C) and 30 C (±3 C), whilst a Binder
CB150 incubator was used for storage at 37 C (±2 C). Sequential
numbers from 1 to 392 were then each randomly assigned to
one of the seven groups and, following storage, all of the 1 ml vials
of vaccine within each group were labeled with one of the numbers
that had been assigned to that particular group. In this manner the
sequential numbers were randomly distributed among the groups.
2.3. Study location and enrollment of dogs – Day-zero
To ensure that most of the dogs recruited into the study were
seronegative for rabies the trial focused on villages that had not
previously been targeted by mass dog rabies vaccination cam-
paigns and are not served by private veterinary services. These tar-
get villages, located within the district of Babati (north-western
Tanzania, GPS 4.32 (lat), 35.60 (long)), were Duru, Endagwe, Ges-
bit, Hoshan and Yarotonik. To locate and recruit dogs for the study,
two field teams travelled on foot from household to household
enquiring at each house whether dogs were owned and, if so,
requesting participation in the study. Owners were asked whether
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unvaccinated dogs being selected. Following the signing of an
informed consent form by the head of the household, all available
dogs were given a full clinical examination. In order to control for
age and body condition only adult dogs (estimated to be between
six months and five years of age) with a body condition score
between two and four inclusive (1 = thin; 5 = fat) were selected
[25]. Following examination, each dog was permanently marked
with a microchip (HomeAgain, Merck Animal Health), assigned
a sequential number and inoculated subcutaneously in the scruff
of the neck with 1 ml of Nobivac Rabies vaccine from the vial with
the same number. Dogs presented for vaccination by the owners,
but that did not fulfill inclusion criteria, were immunized with
standard cold-chain stored vaccine but were not enrolled in the
study. To ensure that participating dogs were seronegative at the
time of a trial, a blood sample was collected prior to vaccination
and stored for post hoc serological analysis. Only dogs with a
pre-vaccination titre of <0.5 IU/ml were included in the analyses.
All dog owners were given a contact telephone number to call if,
following immunization, any adverse effects were seen that were
possibly attributable to the inoculation. Owners were also
informed that dogs could not be considered to have been properly
vaccinated and protected against rabies until after the 4-week fol-
low up when all study dogs would be vaccinated with a dose of
cold-chain stored Nobivac Rabies vaccine.2.4. Follow up visit: Day-28
Twenty-eight days later the field teams returned to the same
households and, following identification using a microchip scan-
ner, each participating dog was given a clinical examination and
a blood sample was collected. During this visit, a 1 ml dose of
cold-chain stored Nobivac Rabies vaccine was inoculated.2.5. Sample processing
All blood samples collected on day zero and day-28 were cen-
trifuged and serum extracted the following day. Sera were stored
at minus 20 C prior to being shipped to the rabies reference labo-
ratory ANSES (France) where serological analyses took place.2.6. Serological analyses
As one of the methods recommended by the OIE Terrestrial
Manual, the Fluorescent Antibody Virus Neutralisation (FAVN) test
[26] was used for detection of antibodies against rabies virus. In
brief, each serum sample as well as the positive and negative con-
trols were distributed in four consecutive wells and serially
diluted. The challenge rabies virus (CVS-11) containing approxi-
mately 100 TCID50/50 ll (TCID50 = 50% tissue culture infective
dose) was added to each well. After 60 min incubation, a volume
of 50 ll of 4  105 BHK21cells/ml suspension was added to each
well and the micro-titre plates were incubated, in a humidified
incubator with 5% CO2, for 48 h at 36 C ±2 C. After incubation,
the plates were stained by adding 50 ll of an appropriate dilution
of a fluorescein isothiocyanate (FITC) anti-rabies monoclonal glob-
ulin to each well. A qualitative reading was performed according to
specific positive fluorescent signal. The Spearman Kärber formula
was used to calculate the LogD50 titres of sera. The titres were
expressed in International Unit per milliliter (IU/ml) by compar-
ison of results obtained with those of the positive standard.
The sera were tested over eight dilutions which allowed the quan-
tification of titres ranging from 0.04 IU/ml (logD50 = 0.24) to
218.26 IU/ml (logD50 = 3.95).2.7. Assessment of a low-tech cooling system
To estimate the temperatures that non-cold-chain stored vaccines
are likely to be exposed to during campaigns, and to assess the effec-
tiveness of a low-tech cooling system, five digital temperature log-
gers (Sensormetrix, www.sensormetrix.co.uk) (loggers 1–5) were
placed in a variety of locations in northern-western Tanzania and
were programmed to record the temperature at midday for 31 con-
secutive days during the hottest period of the year (Feb – March).
To replicate a low-tech method that might be used to keep vaccines
cool when power and refrigerators are not available, loggers 1 and
2 were placed inside vehicles inside insulated vaccine storage boxes
with bottles of water placed around them. The water inside the bot-
tleswas replaced everydayusing local tapwater. Logger3wasplaced
ina similar vaccine storagebox insidea vehiclewithoutwaterbottles.
All of the vehicles were being used on rabies vaccination campaign
duties in villages on the perimeter of the Serengeti - Maasai Mara
ecosystem. Loggers 4 and5wereplaced inside cupboards inbuildings
in the Serengeti -MaasaiMara ecosystem.Thedataweredownloaded
using the software provided and the midday temperature recorded
by each logger for each day of the study period was plotted.
2.8. Statistical analysis
In accordance with the WHO recommendations [24] 0.5 IU per
ml of rabies antibodies is the minimum measurable antibody titre
considered to represent a level of immunity in humans that corre-
lates with the ability to protect against rabies infection. The same
measure is used in dogs and cats to confirm a satisfactory response
to vaccination. As neutralizing antibodies are considered a key
component of the adaptive immune response against rabies virus
[27] antibody titres measured at around 28 days after inoculation
are often used as an indicator of the potency of rabies vaccination
[28,29]. Titre measurements were statistically analyzed using
ANOVA. Post-hoc estimates of the differences between the ele-
vated storage conditions and the cold-chain stored vaccine were
calculated with one-sided 95% confidence intervals. The null
hypothesis, of a storage condition being inferior to the cold-chain
storage, was being tested for each of the elevated conditions in a
hierarchical testing procedure: any given storage condition was
only tested if storage conditions at lower temperatures (but same
duration), and for shorter duration (but at the same temperature),
had been found statistically non-inferior to the cold-chain storage
condition (i.e. the null hypothesis of being inferior had been
rejected). This hierarchical testing procedure is comparable to cer-
tain dose finding studies with ordered hypotheses with increasing
doses [30] and does not need alpha-level adjustment.
An additional exploratory analysis, examining whether storage
conditions impact seroconversion (P0.5 IU/ml), was performed
using a logistic regression model with group and seroconversion
as the explanatory and dependent variables respectively. Finally,
an analysis was performed, according to international regulatory
criteria [31], to determine whether vaccination within each group
was satisfactory. For a group to be determined satisfactory the
group arithmetic mean titre following immunization must be
P0.5 IU/ml and less than 10% of the animals immunizedmust have
a titre lower than 0.1 IU/ml [31].
All statistical analyses were performed using R-statistical envi-
ronment [32].
3. Results
3.1. Safety/clinical issues
Following inoculation there were no adverse events reported by
the dog owners during the 28 day period after vaccination.
Table 2
Estimates and one-sided confidence intervals for the difference of titre levels between
the elevated-temperature stored vaccine groups and the cold-chain stored vaccine
group as derived from ANOVA results.
Estimate Standard error Lower 95% confidence
limit (one-sided)
Group 2 v 1 0.05 0.35 0.54
Group 3 v 1 0.18 0.35 0.75
Group 4 v 1 0.60 0.36 1.19
Group 5 v 1 0.88 0.35 1.46
Group 6 v 1 0.96 0.35 1.54
Group 7 v 1 0.80 0.35 1.39
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reported to have died of unknown causes with non-specific signs.
Although the dates of these deaths were not recorded, the owners
stated that they had occurred closer to the day-28 visit than the
day-zero inoculation. We conclude therefore that these deaths
were not related to vaccination and, further, that any adverse
events that might have been experienced by dogs in any of the
groups were of a mild nature such that the vaccines within each
group can be considered safe.
3.2. Lost to follow up and post-inclusion removal
Because more households were visited per day than was
expected and despite sample size calculations indicating that 350
dogs were required a total of 392 dogs were actually enrolled into
the study and received a day-zero inoculation. At the day-28 visit,
339 of these dogs were available for follow up and were success-
fully re-sampled, 49 were lost to follow-up, and four were
excluded due to operator failure (failed inoculation, sample vol-
ume was too small or the sample was misplaced). Five out of the
392 dogs (1.3%) sampled at day-zero were subsequently found to
have pre-vaccination rabies titres P0.5 IU/ml. Two of these five
dogs were lost to follow up whilst three were included in the
339 dogs re-sampled at day-28. Because these three tested
seropositive at day-zero they were subsequently excluded. As a
result a total of 336 dogs were included in the analyses with
between 46 and 52 dogs per group.
4. Analyses
4.1. Day-28 antibody titre comparison
The primary outcome variable for this study was the day-28
post-vaccination antibody titre. The group geometric means, plus
the mean and standard deviation of the log transformed titre data
are shown in Table 1. The output of the ANOVA analysis, examining
the explanatory effect of group on the log of titre, is presented in
Table 2, whilst Fig. 1 presents a simple graphical summary.
Although a downward tendency can be seen in the level of anti-
body production, the results indicate that groups 2–4 were not
inferior to group 1 according to the pre-set criteria (i.e. the differ-
ence between the groups did not exceed 1.2 log2 titre units). There-
fore for groups 2–4, titres stimulated by Nobivac Rabies vaccine
stored under elevated storage conditions are not more than
1.2 log2 titre units below titres stimulated by cold-chain stored
vaccine. For groups 5–7, titres were not more than 1.2 log2 titre
units below those titres stimulated by cold-chain stored vaccine
but the confidence intervals did not sufficiently exclude this possi-
bility. For this reason we were unable to conclude that groups 5–7
were equivalent to the cold-chain stored vaccine group.Table 1
Group summary data - the number of dogs in each group and the day-28 log mean,
standard deviation, and geometric mean values are shown; day-28 log2 mean and
day-28 SD represent the average and standard deviation of the log (base 2)
transformed data for each group.
Group Number of
dogs
Day-28 log2
mean
Day-28
SD
Day-28
Geometric
mean (IU/ml)
1 50 0.8 1.9 1.8
2 46 0.9 1.7 1.8
3 52 0.6 1.5 1.6
4 46 0.2 1.4 1.2
5 47 0.1 1.8 1.0
6 48 0.1 1.8 0.9
7 47 0.0 2.1 1.04.2. Exploratory analysis: Seroconversion at day-28
An additional exploratory analysis was performed to examine
whether storage conditions impact seroconversion. Fig. 2 summa-
rizes the observed percentages of dogs that seroconverted. The
results of the logistic regression model (Supplementary File 1) sug-
gest that, when compared to group 1, the proportion of dogs that
seroconverted was significantly lower for groups 5–7 (p < 0.05),
whilst for groups 2–4 we were unable to demonstrate any signifi-
cant effect of storage conditions on seroconversion (p > 0.40). As
this analysis had not been specified in the design phase of the
study we consider it exploratory and conclusions are not based
upon the results.4.3. Vaccine assessment
According to international regulatory criteria, a rabies vaccine
can be considered satisfactory if, following immunization, the
group arithmetic mean titre is P0.5 IU/ml and less than 10% of
the animals immunized have a titre lower than 0.1 IU/ml [31].
Applying this definition (using summary data shown in Supple-
mentary File 2), all seven groups had arithmetic mean titres
>0.5 IU/ml and only group 7 had more than 10% of dogs with a titre
<0.1 IU/ml. Under this definition the vaccines from groups 1–6 can
be considered satisfactory at day-28 post-vaccination.4.4. Assessment of a low-tech cooling system
The temperature logger data presented in Fig. 4 shows the
range, and the number of days (count), of each midday tempera-
ture recorded by the five loggers. For loggers 1–5 the maximum
midday temperature (and the number of midday temperatures
that exceeded 30.0 C) were, respectively, 29.6 C (0), 28.4 C (0),
36.7 C (5), 35.7 C (7) and 35.3 (15).5. Discussion
This non-inferiority study has provided the first robust data that
the neutralizing antibody response in dogs vaccinated with Nobi-
vac Rabies vaccine stored for several months at temperatures
far in excess of recommended cold-chain conditions is not inferior
to that of dogs vaccinated with the same vaccine stored under
cold-chain conditions. Specifically the effectiveness of the vaccine
at stimulating rabies antibody was not inferior to cold-chain stored
vaccine when, following cold-chain storage, it was stored for up to
six months at 25 C (groups 2 and 3) or for three months at 30 C
(group 4). These findings were supported by the exploratory anal-
ysis, which suggested that the proportion of dogs that serocon-
verted was not significantly affected when the vaccines were
stored at these same elevated temperature conditions. As the neu-
tralizing antibody response against rabies is considered a surrogate
Fig. 1. A boxplot showing the range of (2log) day-28 titres produced by vaccine stored at elevated temperatures for zero (cold-chain), three or six months (red diamond = 2log
titre mean; G1 – 7 = groups 1–7). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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range of temperatures, is likely to remain efficacious.
Although groups 2–4 were not found to be inferior to cold-chain
stored vaccine, there was a downward tendency in the titre levels
produced by vaccines stored under elevated storage conditions
(Fig. 1). This tendency indicates that storage outside of the cold-
chain does, as expected, impact antibody response. However the
downward tendency was slight, and when applying the criteria
for assessing whether a vaccine is satisfactory were used [31], vac-
cines stored at 30 C for six months (group 5) and 37 C for three
months (group 6) would both be considered satisfactory. Even
group 7 dogs, immunized with vaccine stored at the most extreme
conditions (37 C for six months), had an arithmetic mean titre of2.3, considerably higher than the accepted minimum required anti-
body titre of 0.5 IU/ml [24].
Although we did not generate data on duration of immunity,
titre following primary immunization has, for other viral infec-
tions, been shown to be a robust predictor of induction of central
B cell memory and thus the response upon booster immunization
[33]. As such it is possible that for dogs in groups 2–4 duration of
immunity would not be significantly shorter than those vaccinated
with cold-chain vaccine. Moreover, dogs in canine rabies-endemic
countries are typically vaccinated during annual campaigns, irre-
spective of prior vaccination status, resulting in many dogs being
re-vaccinated every year. Given that the label use of these vaccines
recommends a booster to be given only after every three years, this
WHO seroconversion cut−off titre
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
1 2 3 4 5 6 7
Group
Ti
tre
 IU
 / 
m
l
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therefore consider it unlikely that the duration of immunity of dogs
immunized with vaccines stored under the conditions of groups
2–4 will be a cause for concern. Additionally, many of the 58 dogs
classified as seronegative had a day-28 titre between 0.1 and the
cut off of 0.5 IU/ml (Fig. 3). Some of these dogs may also havesufficient memory to be protected upon challenge and to respond
with protective titres upon boosting.
The promising results from this trial raise several additional
questions pertaining to the thermotolerance of Nobivac Rabies
vaccine: for example, the vaccine was stored under elevated
temperature conditions for up to six months prior to use and it
5510 F.J. Lankester et al. / Vaccine 34 (2016) 5504–5511would be interesting to know for how much longer this vaccine
could be stored whilst retaining equivalent anti-virus antibody
response. Furthermore, the raised temperature conditions that
the trial vaccine was exposed to during the preparation phase
were constant and it would be interesting to examine whether
fluctuating temperature conditions impacts anti-virus antibody
response.
What are the implications of this trial? Thermotolerance was
pivotal in the eradication of small pox and rinderpest as it
allowed emphasis to be placed on community involvement in
both eradication campaigns [21,22]. Furthermore, it has been
shown to increase the effectiveness of the delivery of a number
of human and animal vaccines [20,35]. Thermotolerance could
bring similar benefits to the control of canine-mediated human
rabies. Specifically the availability of a thermotolerant vaccine
could allow novel and cost-effective delivery models for mass
dog rabies vaccination to be developed. For example, the results
will give reassurance that this vaccine might be used effectively
following a period of non-cold-chain storage in remote communi-
ties where access to power and cold-chain storage facilities are
scarce. Further, thermotolerant vaccine could be carefully stored
in remote communities for extended periods allowing dogs to
be vaccinated at various times throughout the year, rather than
annually when mass dog vaccination campaigns pass through.
In this way puppies, born after a central-point vaccination cam-
paign, and new dogs brought into the area, could be vaccinated
in a timely manner, reducing the rate at which the inter-
campaign coverage level decreases. This will be especially useful
in communities where the 70% target has not been reached. Ther-
motolerant vaccine stored in remote areas will also provide a life-
saving resource, for example in the emergency situation of an
outbreak of rabies where rapid vaccination of the dog population
is required to control the epidemic.
To explore the feasibility of transporting and/or storing vaccines
for extended periods in remote areas where power is not available
we compared the midday temperatures recorded in shady parts of
buildings and within insulated vaccine storage boxes placed inside
vehicles with temperatures recorded in similar boxes in which
plastic water bottles, refilled daily with tap water, were placed
(‘low-tech’ cooling system). The results suggested that the temper-
ature inside the low-tech cooling system could be kept cooler than
the ambient temperature of a building or a vehicle. Moreover,
despite a maximum temperature during the study period of
36.7 C, the temperature inside the low-tech cooling systems did
not exceed 30 C. As the tested rabies vaccine was thermotolerant
when stored for three months at this temperature, this result was
encouraging. This was an exploratory analysis and we only inves-
tigated one low-tech system. Further work is required to confirm
whether low-tech systems are able to keep the temperature signif-
icantly lower than the ambient temperature and to explore other,
potentially more effective systems, which could be made available
to vaccinators working in remote areas to keep vaccines cool over
extended periods of time.
In summary, this trial has shown that Nobivac Rabies vaccine
stored at elevated temperatures for extended periods of time
retains its ability to stimulate a neutralizing antibody response.
These preliminary findings are not an indication that the label rec-
ommendations for the storage of this vaccine should be ignored,
however they will give confidence, to programs working with this
vaccine to control rabies, that more flexible delivery models can be
investigated, potentially involving the storage of this vaccine out-
side of the cold-chain for limited periods of time. These findings
will contribute to the recent groundswell of momentum amongst
international human and animal health agencies [4,36] that global
elimination of canine-mediated human rabies is a logistically fea-
sible, cost-effective and socially equitable goal.Conflicts of interest
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